Logo

UG

United-Guardian, Inc.

UG

United-Guardian, Inc. • NASDAQ
$5.79 ▲ 1.94% (+0.11)
Market Cap $26.60 M
52w High $11.98
52w Low $5.58
Dividend Yield 0.60%
P/E 13.47
Volume 3.56K
Outstanding Shares 4.59M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.264M ▼ $710.696K ▼ $268.441K ▼ 11.856% ▼ $0.06 ▼ $353.776K ▼
Q2-2025 $2.838M ▲ $801.918K ▲ $626.826K ▲ 22.085% ▼ $0.14 ▲ $720.607K ▲
Q1-2025 $2.481M ▲ $747.129K ▲ $560.895K ▲ 22.606% ▲ $0.12 ▲ $635.952K ▲
Q4-2024 $2.477M ▼ $725.195K ▲ $503.724K ▼ 20.338% ▼ $0.11 ▼ $582.71K ▼
Q3-2024 $3.06M $702.119K $865.484K 28.283% $0.19 $970.848K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $8.305M ▼ $12.18M ▼ $1.598M ▼ $10.582M ▼
Q2-2025 $8.421M ▲ $13.394M ▲ $1.932M ▲ $11.463M ▲
Q1-2025 $8.121M ▼ $12.763M ▼ $1.928M ▲ $10.836M ▼
Q4-2024 $9.398M ▼ $13.797M ▲ $1.914M ▲ $11.883M ▲
Q3-2024 $9.496M $13.254M $1.875M $11.379M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $268.441K ▼ $1.011M ▲ $-770.109K ▼ $-1.149M ▼ $-907.645K ▼ $995.77K ▲
Q2-2025 $626.826K ▲ $303.243K ▼ $206.316K ▼ $-10.29K ▲ $499.269K ▲ $285.63K ▼
Q1-2025 $560.895K ▲ $322.08K ▲ $679.37K ▲ $-1.608M ▼ $-606.443K ▼ $318.472K ▲
Q4-2024 $503.724K ▼ $269.297K ▼ $-835.558K ▲ $0 ▲ $-566.261K ▲ $-45.876K ▼
Q3-2024 $865.484K $1.229M $-5.584M $-1.608M $-5.963M $1.198M

Revenue by Products

Product Q2-2025Q3-2025
Cosmetic Ingredients
Cosmetic Ingredients
 $0 ▲$0 ▲
Medical
Medical
 $0 ▲$0 ▲
Pharmaceuticals
Pharmaceuticals
 $0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement United-Guardian’s income statement points to a small, niche business with relatively stable sales but earnings that move around from year to year. Profitability appears modest: the company has stayed in the black, but operating profit has been thin recently, with better margins a few years ago than today. Earnings per share dipped after that stronger period and have only partially recovered, suggesting some pressure on pricing, volumes, or costs. Overall, this looks like a steady but low-growth revenue base with profitability that can be sensitive to changes in demand or input costs.

Balance Sheet

Balance Sheet The balance sheet looks conservative and relatively simple. The company carries no financial debt, which reduces financial risk and gives it flexibility in tougher periods. Assets and shareholders’ equity have been quite steady over the past several years, pointing to a business that is not rapidly expanding but also not heavily shrinking. Cash balances move around but are generally present, supporting liquidity. In short, the company appears financially cautious, with a solid equity base and no leverage-driven risk.

Cash Flow

Cash Flow Cash generation broadly follows earnings: positive, but not especially strong. Operating cash flow has been modest and has softened in line with the pressure seen in operating profit. Capital spending has been very light, so free cash flow tends to track operating cash flow quite closely. This “asset‑light” pattern is typical of specialty chemical and formulation businesses and means the company does not need heavy investment to maintain operations, but it also suggests that large organic growth spurts are unlikely without a step‑up in spending or partnerships.

Competitive Edge

Competitive Edge United-Guardian occupies a narrow but defensible niche rather than competing head‑to‑head with global consumer and chemical giants. Its edge comes from specialized hydrogel technologies (such as the Lubrajel line) and long‑standing pharmaceutical products that address focused medical needs. Extensive experience, proprietary formulations, and patents help form a modest moat, and distribution partnerships extend its reach worldwide. However, its small size, reliance on a few key distributors, and exposure to competitive pressures in regions like Asia mean it is vulnerable to shifts in partner strategies and market conditions. The business appears well‑entrenched in its niches but lacks the scale and diversification of larger rivals.

Innovation and R&D

Innovation and R&D Innovation is central to United-Guardian’s identity. The company has built up decades of expertise in hydrogels, with multiple patented formulations and a sizable catalog of products at various development stages. Its established drugs, such as Renacidin and Clorpactin, showcase the long life that successful innovations can have in narrow medical areas. More recently, management has been applying its core technology to growth themes like sexual wellness through the Natrajel line, and to “cleaner” and more natural personal care ingredients. The opportunity is that even small product wins can matter for a company of this size; the risk is that there is limited room for missteps, and the R&D pipeline is not as broad or well‑publicized as those of larger peers.

Summary

Overall, United-Guardian looks like a small, specialized company with conservative finances and a long history of niche innovation. Its strengths include a debt‑free balance sheet, recurring revenues from established proprietary products, and technical know‑how in hydrogels and certain pharmaceuticals. Its main challenges are modest scale, earnings and cash flow that are positive but not robust, dependence on a concentrated set of products and distributors, and competitive pressures in key regions. Future performance will likely hinge on how well it can deepen penetration of its existing pharmaceutical products, revive momentum in personal care ingredients, and successfully commercialize newer lines like Natrajel, all while maintaining its disciplined financial profile.

NEWS

November 6, 2025 · 9:00 AM UTC

United-Guardian Reports Third Quarter Earnings

Read more